Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
17.71
+1.02 (6.11%)
At close: Mar 23, 2026, 4:00 PM EDT
17.81
+0.10 (0.56%)
After-hours: Mar 23, 2026, 7:45 PM EDT
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
The 25 analysts that cover Sarepta Therapeutics stock have a consensus rating of "Hold" and an average price target of $25.24, which forecasts a 42.52% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $81.
Price Target: $25.24 (+42.52%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Sarepta Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 13 | 13 | 13 | 13 | 13 | 13 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 4 | 4 | 4 | 4 | 4 | 4 |
| Total | 29 | 29 | 28 | 28 | 28 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Reiterates $37 | Buy | Reiterates | $37 | +108.92% | Mar 19, 2026 |
| Mizuho | Mizuho | Buy Maintains $26 → $31 | Buy | Maintains | $26 → $31 | +75.04% | Mar 13, 2026 |
| Citigroup | Citigroup | Strong Sell Maintains $8 → $9 | Strong Sell | Maintains | $8 → $9 | -49.18% | Mar 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Sell Reiterates $5 | Strong Sell | Reiterates | $5 | -71.77% | Mar 2, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $45 → $38 | Buy | Maintains | $45 → $38 | +114.57% | Feb 27, 2026 |
Financial Forecast
Revenue This Year
1.76B
from 2.20B
Decreased by -19.75%
Revenue Next Year
1.44B
from 1.76B
Decreased by -18.48%
EPS This Year
3.02
from -7.13
EPS Next Year
2.14
from 3.02
Decreased by -29.13%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.0B | 2.0B | |||
| Avg | 1.8B | 1.4B | |||
| Low | 1.4B | 865.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -9.7% | 11.6% | |||
| Avg | -19.8% | -18.5% | |||
| Low | -36.9% | -50.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 6.06 | 3.91 | |||
| Avg | 3.02 | 2.14 | |||
| Low | 0.47 | 0.94 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 29.3% | |||
| Avg | - | -29.1% | |||
| Low | - | -68.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.